Keating Financial Advisory Services’s Cidara Therapeutics CDTX Stock Holding History

Keating Financial Advisory Services’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$221	–	2581
2025 Q4	$221	Buy	+1	New	+$162	﹤0.01%	2061

Keating Financial Advisory Services's CDTX Position: Q1 2026 in Review

Keating Financial Advisory Services sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1 share — an estimated $221 sold.

Keating Financial Advisory Services first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $221 in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Keating Financial Advisory Services reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Keating Financial Advisory Services sold 1 Cidara Therapeutics share in Q1 2026, an estimated $221.
Keating Financial Advisory Services first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Keating Financial Advisory Services's Cidara Therapeutics position peaked at $221 in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.